Pear Therapeutics, Inc.

Equities

PEARQ

US7047231052

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:37:32 2024-05-15 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

Mar. 22	Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	CI
Mar. 04	Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	CI

Pear Therapeutics, Inc. Reaffirms Revenue Guidance for the Year 2022 and Provides Revenue Guidance for the Year 2023

November 14, 2022 at 04:02 pm EST

Pear Therapeutics, Inc. reaffirmed revenue guidance for the year 2022 and provided revenue guidance for the year 2023. The company reaffirmed its 2022 revenue guidance of $14 million -$16 million.
The company expects 2023 revenue in the range of $27 million to $37 million.

Latest news about Pear Therapeutics, Inc.

Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	Mar. 22	CI
Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	Mar. 03	CI
Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	Feb. 11	CI
Second Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	Dec. 12	CI
First Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	23-08-04	CI
First Motion for Exclusivity Period Extension Filed by Pear Therapeutics, Inc.	23-07-20	CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc.	23-05-23	CI
Motion for Asset Sale Approved for Pear Therapeutics, Inc.	23-05-23	CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	23-05-21	CI
Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	23-05-20	CI
Notice of Auction Resluts Filed by Pear Therapeutics, Inc.	23-05-19	CI
Bidding Procedure Approved for Pear Therapeutics, Inc.	23-04-28	CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from S&P TMI Index	23-04-21	CI
Pear Therapeutics, Inc.(OTCPK:PEAR.Q) dropped from NASDAQ Composite Index	23-04-18	CI
Wall Street Set to Open Lower, March Retail Sales Fall More Than Expected	23-04-14	MT
US Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment Reports	23-04-14	MT
Top Premarket Decliners	23-04-14	MT
Motion for Joint Administration Approved for Pear Therapeutics, Inc.	23-04-12	CI
Top Midday Decliners	23-04-10	MT
Pear Therapeutics Intends to Pursue a Sale of the Business or Assets	23-04-07	CI
Pear Therapeutics, Inc. Announces Executive Changes	23-04-07	CI
Pear Therapeutics, Inc. Announces Resignation of Corey Mccann, M.D., Ph.D. as Chief Executive Officer	23-04-07	CI
Motion for Joint Administration Filed by Pear Therapeutics, Inc.	23-04-07	CI
Motion for Asset Sale Filed by Pear Therapeutics, Inc.	23-04-07	CI
Pear Therapeutics, Inc. Filed for Bankruptcy	23-04-07	CI

Chart Pear Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâs pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
PEAR THERAPEUTICS, INC.	0.00%	142
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.62%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research